Cardiovascular Toxicity Induced by TKIs in Patients with Chronic Myeloid Leukaemia: Are Women and Men Different?
Authors' conclusion
Our study showed a similar frequency of cardiovascular events between men and women. Accurate cardiovascular risk stratification with HFA-ICOS score in cancer patients is crucial. Diabetes and the HFA-ICOS score were significant predictors of events in the female groups. A sex approach in clinical practice could be pursued to improve the appropriateness of care.
Study context
- Population
- Patients diagnosed with chronic myeloid leukaemia (CML) treated with TKIs45% women, mean age: 58 ± 14.2 years
- Participants
- 148 patients
- Comparison
- Men vs women
- Outcome
- Global events
Main finding
As reported in the abstract
P = 0.68
Further findings
HFA-ICOS cardiovascular risk categories
Very high risk
High risk
| Outcome | Men | Women |
|---|---|---|
| HFA-ICOS score predictive efficacy for events | ||
| AUC | 0.537 | 0.797 |
- Event rate by TKI: ponatinib 41%
- Event rate by TKI: nilotinib 32%
- Event rate by TKI: imatinib 32%
Cardiovascular event during TKI therapy
- Experienced a cardiovascular event
- 33%
- Sex difference in arterial thrombosis incidence
- P = 0.02
- Sex difference in venous thrombosis incidence
- P = 0.02
Event risk by HFA-ICOS score
- Very high HFA-ICOS score HR
- 3.07; CI 1.11, 8.47 P = 0.03
- High HFA-ICOS score HR
- 3.29; CI 1.17, 9.26 P = 0.02
- Particularly in women
Diabetes as predictor of events in women
- Diabetes HR
- 5.40; CI 1.37, 21.3 P = 0.01
- Women's strongest predictor of events
Original publication
Cardiovascular Toxicity Induced by TKIs in Patients with Chronic Myeloid Leukaemia: Are Women and Men Different? ESC Heart Fail. Published 9 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →